Articlenpj women's health2025
Predicting oxytocin binding dynamics in receptor genetic variants through computational modeling.
Article in npj women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Approximately half of U.S. women giving birth annually receive Pitocin, a synthetic form of oxytocin (OXT), yet the optimal dosing remains challenging due to significant individual variability in response. To address this, we developed a mathematical model examining the effects of five OXT receptor (OXTR) variants (V45L, P108A, L206V, V281M, and E339K) on OXT-OXTR binding dynamics in human embryonic kidney cells (HEK293T) and myometrial smooth muscle cells. The model was parameterized using experimentally derived, cell-specific OXTR surface localization measurements and literature-reported OXT-OXTR-binding kinetics. The model revealed differences in time to equilibrium between HEK293T and myometrial cells, distinct dynamics among genetic variants, and that early increases in OXT could partially rescue diminished responses in V281M and E339K variants. This model provides key insights into how genetic variants influence OXT dose responses and offers a framework for tailoring OXT dosing to patient-specific genetic profiles.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.